+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Multiple Myeloma Drug"

From
From
Global Multiple Myeloma Drugs Market 2023-2027 - Product Thumbnail Image

Global Multiple Myeloma Drugs Market 2023-2027

  • Report
  • October 2022
  • 120 Pages
  • Global
From
From
From
From
From
From
Multiple Myeloma: Epidemiology Forecast to 2027 - Product Thumbnail Image

Multiple Myeloma: Epidemiology Forecast to 2027

  • Report
  • March 2019
  • 42 Pages
  • Global
From
From
Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2020 - Product Thumbnail Image

Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 2289 Pages
  • Global
From
From
From
Loading Indicator

Multiple Myeloma is a type of cancer that affects the plasma cells in the bone marrow. It is a form of Leukemia, and is the second most common type of blood cancer. Treatment for Multiple Myeloma typically involves a combination of chemotherapy, radiation therapy, and targeted drug therapy. The Multiple Myeloma drug market is composed of a variety of drugs, including proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, and other targeted therapies. These drugs are used to treat the disease, as well as to reduce the risk of relapse. The Multiple Myeloma drug market is highly competitive, with many companies offering a range of treatments. Some of the major players in the market include Bristol-Myers Squibb, Celgene, Novartis, Amgen, and Johnson & Johnson. Other companies such as Merck, Pfizer, and Takeda are also active in the market. Show Less Read more